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ABSTRACT
Type IB DNA topoisomerases can eliminate torsional
stresses produced during replication and transcrip-
tion. These enzymes are found in all eukaryotes and
a short version is present in some bacteria and
viruses. Among prokaryotes, the long eukaryotic ver-
sion is only observed in archaea of the phylum Thau-
marchaeota. However, the activities and the roles of
these topoisomerases have remained an open ques-
tion. Here, we demonstrate that all available thaumar-
chaeal genomes contain a topoisomerase IB gene
that defines a monophyletic group closely related
to the eukaryotic enzymes. We show that the topIB
gene is expressed in the model thaumarchaeon Ni-
trososphaera viennensis and we purified the recom-
binant enzyme from the uncultivated thaumarchaeon
Candidatus Caldiarchaeum subterraneum. This en-
zyme is active in vitro at high temperature, mak-
ing it the first thermophilic topoisomerase IB char-
acterized so far. We have compared this archaeal
type IB enzyme to its human mitochondrial and
nuclear counterparts. The archaeal enzyme relaxes
both negatively and positively supercoiled DNA like
the eukaryotic enzymes. However, its pattern of DNA
cleavage specificity is different and it is resistant to
camptothecins (CPTs) and non-CPT Top1 inhibitors,
LMP744 and lamellarin D. This newly described ther-
mostable topoisomerases IB should be a promising
new model for evolutionary, mechanistic and struc-
tural studies.
INTRODUCTION
DNA topoisomerases are essential enzymes found in all or-
ganisms [for reviews see (1–6)]. TheymodifyDNA topology
by introducing reversible breaks into the DNA phosphodi-
ester backbone. Topoisomerases accomplish their task ei-
ther by cleaving one strand of the DNA duplex and pass-
ing the intact complementary strand through the nick (type
I topoisomerase), or by cleaving both strands and pass-
ing an intact duplex segment through the double-strand
break (type II topoisomerase). Type I enzymes are classi-
fied into three families: types IA, IB and IC, each of them
characterized by specific combinations of non-homologous
domains (7). Type IB enzymes (TopIB) are distantly re-
lated to tyrosine recombinases (8). These enzymes can relax
both positive and negative superturns in vitro. They form
a tyrosyl-3′-phosphodiester linkage and the cleavage gener-
ates a transient swivel allowingDNA strands to rotate freely
around each other until religation occurs [for type IB topoi-
somerases structures and mechanisms see (3,6,9–12)].
The type IB enzyme (Top1) was the first DNA topoiso-
merase discovered in eukaryotes by James Champoux in
1972 (13). Since TopIB enzymes are capable of relaxing pos-
itive superturns, it was anticipated that these enzymes, as
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well as type II DNA topoisomerases, are likely to play a
major role in the elimination of torsional stress that accu-
mulates as positive superturns in front of replication forks
or of transcription bubbles (14–17). Indeed, genetic analy-
ses and the use of specific DNA topoisomerase inhibitors
have not only shown that type IB and IIA DNA topoi-
somerases probably cooperate in removing torsional stress
during replication and transcription, but also in chromatin
formation and chromosome condensation (2,18–23). In line
with its critical role in cell physiology, human DNA topoi-
somerase IB is an important drug target in antitumoral
treatments, since cancerous cells are very sensitive to poi-
sons that inhibit this enzyme (6,23). The TopIB inhibitors
reversibly stabilize the intermediate covalent TopIB–DNA
complex that is formed during the relaxation reactions, pre-
venting the religation (22,24,25). This is why the human
DNA topoisomerase IB and a few other enzymes of this
family, mainly the one of Vaccinia virus (26) and of the bac-
teriumDeinococcus radiodurans (27), have been under inves-
tigation by several laboratories during the last four decades.
topIB genes have been found in all eukaryotic genomes se-
quenced so far. In vertebrates, a specific TopIB with a much
shorter N-terminal sequence is also present in mitochon-
dria (28,29). Homologs of TopIB that are smaller versions
of the eukaryotic ones have been also detected in Poxviruses,
Mimivirus and in several bacterial genomes (26,27,30,31).
They are quite different from their eukaryotic counterparts,
since they harbor a specific domain (virDNA-Topo-I N) in
theirN-terminus, instead of the longTopoisom I Ndomain
found in eukaryotic homologs (32).
For a long time, it was thought that the type IB enzyme
was not present in the archaeal domain. However, a gene
encoding a large version of a DNA topoisomerase IB, very
similar to the eukaryotic enzyme, was ultimately detected
in the genome of the mesophilic archaeon Cenarchaeum
symbiosum, a sponge symbiont and of Nitrosopumilus mar-
itimus, the first thaumarchaeon successfully cultivated in
the laboratory (32). These species turned out to be rep-
resentative of a third major archaeal phylum, the Thau-
marchaeota, alongside the two other previously described
archaeal phyla, the Euryarchaeota and the Crenarchaeota
(33). The Thaumarchaeota are widespread in all types of en-
vironments and most of them play an important role in the
nitrogen cycle (34). Therefore, since their discovery, Thau-
marchaeota have been extensively studied, notably because
of their ecological importance.
Phylogenetic analyses have suggested that the type IB en-
zyme from Thaumarchaeota was present in the last com-
mon ancestor of Archaea and Eukarya and was later on
lost in Euryarchaeota and Crenarchaeota (32). However,
these studies were based on the in silico analyses of complete
genomes of only two species of Thaumarchaeota. These
last years, genes encoding type IB enzymes have been de-
tected in the genomes of all other characterized Thaumar-
chaeota whose genomes have been sequenced, as well as in
the genome of the uncultivated species Ca. Caldiarchaeum
subterraneum. It has been proposed to considerCa. C. sub-
terraneum as a member of a new phylum, Aigarchaeota
(35). However, all the features first used to define the Thau-
marchaeota (33,36) are present inCa. C. subterraneum and
this organism forms a monophyletic group with the Thau-
marchaeota in most phylogenetic analyses (37–40), suggest-
ing that Ca. C. subterraneum can be considered as a deep-
branching thaumarchaeon (41).
The ubiquity of type IB enzymes inThaumarchaeota sug-
gests that the genes encoding these enzymes can be con-
sidered as a hallmark of this major archaeal phylum. Yet,
the phylogenetic position of all thaumarchaeal type IB en-
zymes, their enzymatic activities and their expression in vivo
remained to be clarified (10). In this study, we establish that
all Thaumarchaeota studied so far contain a type IB en-
zyme that forms a monophyletic group, closely related to
eukaryotic enzymes in a global type IB phylogeny. We show
that the topIB gene is expressed in Nitrososphaera viennen-
sis, a cultivated thaumarchaeon isolated from a soil in Vi-
enna (42,43). Finally, we purified the enzyme and character-
ized the activities of the TopIB enzyme from Ca. C. subter-
raneum (Cs-TopIB) and compared it with nuclear andmito-
chondrial human topoisomerases IB [Hs-Top1 (Top1) and
Hs-Top1mt (Top1mt)]. Our results demonstrate that the Cs-
TopIB enzyme is functional, with all the known activities of
eukaryotic TopIB proteins. However, in contrast to the hu-
man DNA topoisomerases IB, the archaeal enzyme is resis-
tant to the antitumoral drug camptothecin (CPT) (23). Our
results are also in good agreement with the thermophilic
nature of Ca. C. subterraneum, since its type IB enzyme
is active in a wide range of temperatures, from 10 to 80◦C.
Taken together, our results suggest that the type IB enzymes
of Thaumarchaeota could become promising new models
to study the biochemistry and evolution of this important
class of enzymes.
MATERIALS AND METHODS
Plasmids and reagents
Negatively supercoiled plasmid pBR322 DNA was pur-
chased from Fermentas Life Science and kinetoplast
DNA (kDNA) from Topogen. The reverse-gyrase enzyme
was kindly given by Prof. Marc Nadal (Universite´ Paris
Diderot). Primers were synthesized byMWG-Operon. CPT
was from Developmental Therapeutics Program (DTP),
DCTD, NCI, NIH and dissolved in dimethylsulfoxide
(DMSO) at 10 mM final concentration as a stock solution.
Bacterial and archaeal strains and culture media
Escherichia coli strains XL10-Gold and BL21(DE3) were
used for cloning and expressing topIB, respectively. These
strains were grown in Lysogeny Broth (LB) medium. N.
viennensis strain EN76 (42,43) was used to detect the ex-
pression of topIB and was cultivated in fresh water medium
(FWM) supplemented as described in (43).
Phylogenetic analysis
Homologs of TopIB were gathered from the nr (non-
redundant) amino acid sequence databank using PSI-
BLAST (44) with different distantly related queries (i.e.
Eucarya Homo sapiens NP 003277, Bacteria Rhodobac-
ter sphaeroides YP 354029, Archaea C. symbiosum
WP 013481455 and Megavirales Acanthamoeba polyphaga
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mimivirus YP 003986690 sequence queries). A represen-
tative sequence subset was extracted and aligned with
MAFFT (45). Well-suited characters were selected with
BMGE (46) and used to infer an ML phylogenetic tree
with PhyML [evolutionary model LG + G4 + I and 1000
bootstrap replicates (47,48)].
RNA extraction
Batches of 10 ml N. viennensis cultures were grown to
mid-exponential phase at 37◦C without agitation in FWM
medium containing 1 mM NH4Cl (43). Growth was mon-
itored by dosing the concentration of nitrite formed over
time in the culture medium. For all subsequent steps, solu-
tionswere preparedwith nuclease-free water and, when pos-
sible, DEPC-treated overnight and autoclaved. A total of 80
ml of cultures were harvested by centrifugation at 8000 g,
for 25 min at 4◦C. The cell pellet was resuspended by pipet-
ting in 400 l of Acidic Buffer (50 mM CH3COONa, [pH
5.3] and 10 mM ethylenediaminetetraacetic acid (EDTA)).
Forty microliters of a 20% sodium dodecyl sulfate (SDS)
solution was added and the tube mixed by vortexing. One
volume (440 l) of phenol equilibrated with Acidic Buffer,
preheated to 65◦C, was added to the sample, which was in-
cubated for a further 4 min at 65◦C, before freezing in liquid
nitrogen and storing overnight at −80◦C. After centrifuga-
tion at 16 000 g for 15min at room temperature, one volume
of phenol/chloroform was added to the aqueous phase and
centrifuged at 16 000 g for 5 min at room temperature. Af-
ter precipitation of the nucleic acids present in the aquaeous
phase, the pellet was resuspended in 15 l of nuclease-free
water. Two DNAse treatments and purification using the
RNEasy MinElute Kit (Qiagen) were then performed sub-
sequently to obtain RNA free of DNA traces. The final
RNA yield was about 200 ng.
Endpoint RT-PCR
Forty nanogram of total RNA were mixed with 1 l of
2 M Nv-TopIB specific reverse primer R2 (5′-TCTTGC
GAGTTCCTGTCCAC), 1 M of 10 mM dNTPs and the
final volume adjusted to 10 l with nuclease-free water.
RNAs were denatured by heating at 65◦C for 5 min and
then placed on ice for 2 min. Ten microliters of Superscript
III (Promega) reverse-transcription mixture (2 l 10× RT
buffer, 4 l 25 mM MgCl2, 2 l 0.1M DTT, 1 l RNAse-
Out and 1 l Superscript III) were added and the reverse-
transcription performed at 50◦C for 50 min. The reaction
was terminated by incubating at 85◦C for 5 min and sub-
sequent chilling on ice. RNAs were digested by the ad-
dition of 1 l of RNAse H and incubating at 37◦C for
20 min. Four microliters of cDNAs from the RT reaction
were used for polymerase chain reaction (PCR) amplifica-
tion with the GoTaq2 PCR kit (Promega), using 2 l of
the 10 M reverse primer R2 and forward primer F2 (5′-
CGGCAGGGCAATGATAAAGC) in a final 50 l reac-
tion. An initial denaturation step of 2 min at 94◦C was fol-
lowed by 33 PCR cycles (94◦C, 30 s/55◦C, 40 s/72◦C, 1 min
30 s). To control for possible DNA contaminations in work-
ing solutions, a ‘H2O’ control was performed with nuclease-
free water. To control for complete DNA digestion of the
RNA preparation a ‘-RT’ control was performed, in which
Superscript III was substituted with 1 l of nuclease-free
water.
Protein structure predictions
Structural predictions were performed with the Phyre2 web
server (49). Comparisons between different topoisomerases
models were conductedwith the PyMOLMolecularGraph-
ics System (http://www.pymol.org).
Recombinant protein expression and purification
The topIB gene from Candidatus C. subterraneum (gene
ID: 557694258) was synthesized by GeneArt Gene Synthe-
sis (Life Technologies). The codon usage for expression in
E. coli was optimized using the GeneArt Gene Synthesis
built-in application. The synthetic gene was cloned with an
N-terminal His-Tag into the pETM-11 vector. The plasmid
was transformed into E. coli and the cultures were grown
subsequently in 1–4 l of LB medium containing kanamycin
(50 g/ml). Induction of the expression of Ca. C. sub-
terraneum topoisomerase IB (Cs-TopIB) was carried out
for 1 h at 37◦C, after the addition of 1 mM isopropyl-
D-1-thiogalactopyranoside when cell cultures reached an
OD600 nm of 0.8. Cells were then harvested by centrifu-
gation, stored overnight at −80◦C, and then suspended in
a 50 mM Tris–HCl [pH 8] and 1 M KCl buffer contain-
ing a protease cocktail (Sigma Aldrich). Cell lysis was com-
pleted by sonication. The lysed cells were then incubated
at 75◦C for 15 min and centrifuged for 60 min at 15 000
rpm at 4◦C. The supernatant was filtered through a 0.2 m
filter membrane and loaded onto a Ni-NTA column (His-
Select HF Nickel Affinity Gel, Sigma-Aldrich). The frac-
tions were eluted with 500 mM imidazole in the presence of
50 mM Tris–HCl [pH 8] and 150 mM NaCl. Cs-TopIB en-
zymewas assessed for purity on a Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Fractions
containing the TopIB polypeptide were pooled and con-
centrated with Amicon 3 kDa cut-off concentrators (Milli-
pore). The protein concentrationwas determined byUVde-
tection method at 280 nm or a Bradford assay. The concen-
trated fractions were dialyzed against 50 mM Tris HCl [pH
8], 1M NaCl and 50% glycerol (v/v), aliquoted and stored
at −20 or −80◦C.
In vitro mutagenesis
The plasmid bearing Cs-topIBY477F gene was generated
with the QuikChange Lightning Site-DirectedMutagenesis
kit (Agilent Technologies) using primers TpIb a1430t (5′-
ACCAGCCTGCGTAACTtTATTGATCCGCGTGTG)
and TpIb a1430t a (5′-CACACGCGGATCAATAaA
GTTACGCAGGCTGGT). Mutations in the primer
sequences compared to the Ca. C. subterraneum reference
sequence are indicated by lowercase letters. After mutage-
nesis, the plasmids were purified with NucleoSpin Plasmid
(Macherey Nagel).
Positively supercoiled pBR322 preparation
Positively supercoiled pBR322 was prepared by incubation
of a negatively supercoiled pBR322 plasmid for 30 min
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at 85◦C in the presence of Sulfolobus solfataricus reverse-
gyrase in buffer containing 40mMTris–HCl [pH 8], 20 mM
MgCl2, 1 mM adenosine triphosphate (ATP) and 1 mM
DTT. The reaction was stopped by adding 10 mM EDTA
and 200 mM NaCl (M. Nadal, personal communication).
The positively supercoiled plasmid was purified with the
NucleoSpinGel and PCRClean-up kits (Macherey-Nagel).
DNA relaxation, decatenation and supercoiling assays
Relaxation assays were performed in a final volume of 20
l with negatively, positively or relaxed supercoiled pBR322
plasmid or kDNA (200 ng) and the indicated amount of en-
zyme, in the Cs-TopIB buffer containing 40 mM Tris–HCl
[pH 8], 2 mM DTT, 1 mM spermidine and 100 mM KCl
or in the human-TopIB buffer containing 10 mM Tris–HCl
[pH 8.5], 0.1 mM EDTA, 15 g/ml bovine serum albumin
(BSA) and 50 mM KCl. The reactions were performed for
0–30 min at different temperatures depending on the assay
and were stopped by adding 0.5% SDS on ice. A total of 2
l of proteinase K (1 mg/ml) were then added for an ad-
ditional incubation of 30 min at 55◦C. The reactions were
stoppedwith the blue charged electrophoretic buffer. All the
reactions were loaded on a 1% agarose gel prepared in 0.5
×Tris-Acetate-EDTA (TAE) buffer (45 mMTris–base, [pH
8.5] and 1 mM EDTA). The gels were run at 50 V for 4 h,
then stained with ethidium bromide and visualized with a
Gel Imaging system (Vilber). Quantification of the pBR322
relaxation was done by estimating the disappearance of the
supercoiled DNA using the NIH ImageJ application.
DNA cleavage assays
Site cleavage specificity of TopIB was determined with lin-
ear pSKDNA (50). Briefly, a 3′-end labeled double stranded
118-bp DNA substrate was incubated with TopIB in 10 l
reaction buffer [10 mmol/l Tris–HCl (pH7.5), 50 mmol/l
KCl, 5 mmol/l MgCl2, 0.1 mmol/l EDTA and 15 mg/ml
BSA] at 25◦C for 20 min in the presence of the drugs spec-
ified in the figures. Reactions were terminated by adding
SDS (0.5% final concentration) followed by the addition of
two volumes of loading dye (80% formamide, 10 mmol/l
sodium hydroxide, 1 mmol/l sodium EDTA, 0.1% xylene
cyanol and 0.1% bromphenol blue). Aliquots of each sam-
ple were subjected to 20% denaturing PAGE. Gels were
dried. The cleavage patterns were visualized using a Phos-
phoimager and ImageQuant software (Molecular Dynam-
ics). Cleavage sites were numbered as previously described
(51).
In vitro assays with camptothecin
Activities of TopIB in the presence of CPT were tested with
relaxation kinetics assays. The assays were realized follow-
ing the same protocols as described in the relaxation assays,
with addition of CPT at a concentration of 50 M or with
5% DMSO as control.
RESULTS
Phylogenetic analysis of type IB DNA topoisomerases
Our search for type IB DNA topoisomerases in ar-
chaeal genomes demonstrates that all completely sequenced
genomes of Thaumarchaeota contain this protein-coding
gene. Phylogenetic analysis using representative subsets
of sequences for Thaumarchaeota, Eukarya, Bacteria and
Nucleo-Cytoplasmic Large DNA Viruses (NCLDV) (Fig-
ure 1; for the complete tree, see Supplementary Figure
S1) shows that all thaumarchaeal sequences form a mono-
phyletic group, including Ca. C. subterraneum. Surpris-
ingly,Ca.C. subterraneum branch within Thaumarchaeota
and not as a sister group of other Thaumarchaeota, as ob-
served in most phylogenies. However, the confidence sup-
port of the corresponding node is quite low (i.e.<70%), sug-
gesting that this emerging position is not robustly supported
by the data. Thaumarchaeal type IB enzymes are closely
related to eukaryal sequences (long form) in the phyloge-
netic tree, being very distant from bacterial andNCLDV se-
quences (short forms). However, they are clearly separated
from Eukarya. Notably, we recover the monophyly of most
eukaryal divisions in our analysis, suggesting that the root
of the eukaryal part of the tree indeed corresponds to the
last eukaryal common ancestor.
The topIB gene is expressed in Nitrososphaera viennensis
The topoisomerase IB gene is found in all thaumarchaeal
genomes sequenced to date, but up to now nothing was
known neither about the role and the activities of the en-
coded protein nor about the expression of the correspond-
ing gene. We first determined by endpoint RT-PCR if the
topIB gene is expressed in Thaumarchaeota using as a
model the mesophilic thaumarchaeon N. viennensis, one
of the few cultivated Thaumarchaeota to date (42,43). We
chose to amplify a 533-bp fragment spanning from the mid-
dle toward the 3′ end of the 1686 bp predicted topIB gene
(Figure 2A and B). Because in eukaryotes TopIB enzymes
have major roles in replicating cells, we prepared RNA sam-
ples fromN. viennensis actively growing (generation time of
ca. 27 h) by collecting the cells in the late part of the expo-
nential growth phase. RT-PCR results showed the expected
band at around 533 bp (Figure 2C). Gel excision, purifi-
cation and sequencing of the obtained PCR product con-
firmed that it corresponds to the topIB gene ofN. viennensis.
Faint lower molecular weight bands, possibly due to RNA
secondary structures and/or an imperfect RT reaction can
be seen below the major band (Figure 2C). These results in-
dicate that the topIB gene is expressed in N. viennensis.
Identification and purification of Candidatus Caldiarchaeum
subterraneum TopIB protein
Although this thaumarchaeon has not yet been isolated and
thus cannot be cultivated, we chose the thermophilic species
Ca. C. subterraneum for the biochemical characterization
of the archaeal topoisomerase IB. As indicated by its name,
the genomic DNA of this organism originated from a sub-
surface gold mine at a temperature of 70◦C, and genome
analysis showed the presence of a gene coding for a reverse
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Figure 1. Schematic representation of the unrooted phylogenetic tree of TopIB homologous sequences. Specified taxon names are colored according to their
membership, i.e. Thaumarchaeota (orange), Excavata (blue), Viridiplantae (green), SAR (dark magenta), Amoebozoa (dark blue), Opisthokonta (cyan).
Remaining taxon names (black) each are the only member of their respective phylum, i.e. Emiliania huxleyi (Hacrobia) and Guillardia theta (Cryptophyta).
Terminal branches corresponding to Bacteria (gray), Phycodnaviridae and Poxviridae (dark red) clades are shown as triangles of depth proportional to
internal diversity (for more details, see Supplementary Figure S1). Bootstrap-based branch supports are indicated at branches. The scale bar represents the
average number of substitutions per character.
gyrase. This type IB enzyme would thus be the first ther-
moresistant DNA topoisomerase IB characterized, which
might facilitate its purification and further structural anal-
yses. We retrieved the Ca. C. subterraneum topoisomerase
IB (Cs-TopIB) protein sequence (GenBank: BAJ49459.1)
from NCBI. The protein is 539 amino-acid residues long.
The two characteristic topoisomerase IB domains (Topoi-
som I N and Topoisom I) are present and are separated by
a linker domain. As already observed for other thaumar-
chaeal TopIB proteins (32), Cs-TopIB does not possess the
variable charged N-terminal region of the protein observed
in the nuclear eukaryotic enzymes (29) and the linker do-
main is smaller (53 amino acids instead of 76 for human
TopIB) (Figure 3A). Alignment of Cs-TopIB with the hu-
man nuclear ortholog shows 37% identity (57% similarity)
for the core domain and 43% (52% similarity) for the C-
terminus domain. Alignement of Cs-TopIB with the mito-
chondrial ortholog (Top1mt) shows 34% identity (54% sim-
ilarity) for the core domain and 38% (52% similarity) for the
C-terminus domain. (Supplementary Figure S2).
A multiple sequence alignment of Cs-TopIB with other
thaumarchaeal and eukaryotic topoisomerases IB shows
that the active site residues (the catalytic tetradR488, K532,
R590 and Y723) are conserved, suggesting the functional-
ity of the thaumarchaeal proteins (Figure 3B). Cs-TopIB
share 52, 53 and 49% identity with the TopIB ortholog of
C. symbiosum, N. maritimus and N. viennensis, respectively.
We compared the human TopIB structure (PDB ID: 1T8I)
with the 3D predicted structure of the Cs-TopIB obtained
with the Phyre2 web-server, using the molecular visualiza-
tion system PyMol (Schro¨dinger) (Figure 3C). The two pro-
teins show 95% of structural identity and can be superim-
posed, except for parts of their linker domains (Figure 3C).
TheCandidatusCaldiarchaeum subterraneum TopIB protein
has typical type IB topoisomerase enzymatic activities
The Cs-TopIB protein expressed with an N-terminal His-
tag, was purified after expression inE. coli from a codon us-
age optimized Cs-topIB synthetic gene. The Cs-TopIB pro-
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Figure 2. Expression of topIB inNitrososphaera viennensis. (A) Positions of
the forward and reverse primers F2 andR2 on the 1686 bp coding sequence
of the N. viennnensis Nv-topIB gene. (B) Amplification using primers F2
and R2 on DNA from 1 l of a growing N. viennensis culture, yielding
the expected 533-bp fragment. (C) Endpoint RT-PCR using primer R2 for
the reverse transcription and primers F2 and R2 for the PCR amplifica-
tion. ‘H2O’: RNA was substituted with nuclease-free water in the RT re-
action. ‘−RT’: 1 l of nuclease-free water was used instead of Superscript
III reverse transcriptase in the RT reaction. Using 40 ng of total RNA,
the expected band at 533 bp could be amplified by RT-PCR (panel ‘+RT’,
indicated by a star). The 533-bp band was excised from the gel and the cor-
responding DNA purified and sequenced, matching the publicly available
sequence of the N. viennensis Nv-topIB coding gene.
tein migrates on a SDS-PAGE gel at about 60 kDa, close
to the theoretical mass of 63 kDa (Supplementary Figure
S3A).
The purified Cs-TopIB turned out to be active in vitro.
The enzyme relaxed negatively supercoiled plasmid pBR322
in the presence of monovalent salt (NaCl or KCl). As ex-
pected for a typical topoisomerase IB enzyme, the observed
activitywasATP- andmagnesium-independent. The in vitro
activity was optimal from 150 to 250 mMKCl (Supplemen-
tary Figure S3B), which is higher than the KCl concentra-
tion (50 mM) used for in vitro human topoisomerases IB
relaxation assays (26). The enzyme was active across an un-
precedentedly wide temperatures range (from 10 to 80◦C),
with optimal activities between 40 and 70◦C (Figure 4A).
Time course Cs-TopIB relaxation assay at 70◦C shows than
the enzyme is processive, as its human counterparts (Top1
and Top1mt), as fully relaxed DNA started to accumulate
during the first minute of the reaction, whereas most of the
substrate was still fully negatively supercoiled. Topoisomers
with intermediate supercoiling density never appeared in
the course of the reaction (Figure 4B).
To control for potential contamination of Cs-TopIB
preparation with other DNA topoisomerases that could re-
lax the DNA substrate, we constructed a mutant of Cs-
TopIB in which the predicted catalytic tyrosine 477 (Y477)
in Cs-TopIB, which corresponds to the tyrosine 723 in the
human protein (Figure 3B), was changed to a phenylala-
nine. This substitution, which does not change the predicted
overall protein structure eliminates the potential phoshodi-
ester bond formation because of the absence of the phe-
nolic hydroxyl group. Relaxation assays at 30◦C using the
Cs-TopIBY477F mutant protein and negatively supercoiled
pBR322 plasmid DNA as a substrate showed no relaxation
activities by comparison with the wild-type enzymes (Sup-
plementary Figure S3C), demonstrating that the relaxation
observed with the wild-type Cs-TopIB preparation was not
due to a contamination. In addition, we testedCs-TopIB de-
catenation and supercoiling activities. As expected for a typ-
ical topoisomerase IB enzyme, the results showed that Cs-
TopIB has neither of these activities (Supplementary Figure
S3D).
CandidatusCaldiarchaeum subterraneumTopIB is thermore-
sistant
The purified Cs-TopIB was pre-heated for 20 min at differ-
ent temperatures (from 37 to 75◦C) before testing its relax-
ation activity at 65◦C. Figure 5A shows that the enzyme was
still active after preincubation for 20 min at 75◦C. This ther-
moresistance was then used to facilitate the purification of
the protein by heating of the E. coli cell lysate at 75◦C for 15
min before theNi-NTA column step. These results, together
with the observation that the enzyme is still fully active at
80◦C are in agreement with the thermophilic nature of Ca.
C. subterraneum and make Cs-TopIB the first thermoresis-
tant topoisomerase IB characterized to date.
In contrast to the type IA topoisomerases, TopIB en-
zymes are known to relax both negatively and positively
supercoiled DNA. This is indeed the case for Cs-TopIB.
As shown in Figure 5B, Cs-TopIB relaxed positively super-
coiled pBR322 whereas the E. coli Topo IA was inactive
on this substrate. We observed that at 30◦C, Cs-TopIB re-
laxed negatively and positively supercoiled pBR322 plas-
mid DNA at the same rate and was processive on both
substrates (Supplementary Figure S4). Adding the diva-
lent cation Mg2+ stimulated slightly the relaxation activity
of Cs-TopIB with negative DNA substrate, consistent with
the Hs-Top1 or Hs-Top1mt enzymes (Figure 5C) (28,52).
Comparison of the Cs-TopIB DNA relaxation activity un-
der different DNA/protein ratio confirmed that Cs-TopIB
is processive under our reaction conditions similarly to the
human DNA relaxation reactions (Supplementary Figure
S3C, Cs-TopIBwt).
Candidatus Caldiarchaeum subterraneum TopIB is resistant
to camptothecin and exhibits a different cleavage complex se-
lectivity
The antitumoral drug CPT reversibly traps the eukary-
otic topoisomerase IB–DNA complex, inhibiting or slow-
ing down the religation of the cleaved DNA strand (22,53).
As a consequence, this drug both inhibits the relaxation ac-
tivity of the enzyme and stimulates DNA cleavage. Eukary-
otic nuclear type IB topoisomerase (Hs-Top1) is very sensi-
tive to molecules from the CPT family, while mitochondrial
type IB topoisomerase (Hs-Top1mt) is also sensitive, but to
a lesser extent (28).
We tested the effect of CPT on the kinetics of relaxation
by Cs-TopIB, Hs-Top1 and Hs-Top1mt at a concentration
of 50 M and at 30◦C, usually used for this type of analy-
ses (50). As shown in Figure 6A, CPT had no effect on the
relaxation activity of Cs-TopIB on negatively supercoiled
DNA substrate under conditions where it inhibited the re-
laxation activities of the Hs-Top1 and to a lesser extent of
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Figure 3. Conserved domains and catalytic residues of Thaumarcheal TopIB. (A) Domain organization of human Top1 (Hs-Top1) and Cs-TopIB. In purple
the non-conserved eukaryotic N-terminal domain, in green the conserved Core domain, in red the Linker domain, in blue the C-terminal domain with
the catalytic tyrosine and in light green a small Cs-TopIB additional C-terminal domain. (B) Multiple amino-acid sequence alignments of topoisomerase
IB in proximity of the active site. Amino acids in the active site (R488, K532, R590, H632, Y723) are marked with a + and their numbering is based on
the human protein. The aligned sequences are from Candidatus Caldiarchaeum subterraneum (C.sub), Cenarchaeum symbiosum (C.sym), Nitrosopumilus
maritimus (N.m), Nitrososphaera viennensis (N.v), Homo sapiens (H.s), Mus musculus (M.m) and Arabidopsis thaliana (A.t). Residues conserved in all
sequences are highlighted in yellow. The tyrosine 477 of Ca. C. subterraneum mutated to a phenylalanine corresponds to Y723 of the human protein. (C)
Ribbon representation of the crystal structure of the human Top1 in yellow (PDB ID: 1K4T) and the Cs-TopIB molecular model in blue. Camptothecin
(CPT) and catalytic tyrosine are rainbow colored.
the Hs-Top1mt. Similarly, the presence of CPT does not af-
fect the activity of TopIB on the positively supercoiledDNA
(Figure 6B).
To further evaluate the lack of response of Cs-TopIB
to CPT, we analyzed the patterns of DNA cleavage of
Cs-TopIB in comparison with Hs-Top1 and Hs-Top1mt
on linear DNA in the absence and presence of CPT (50).
While the two human enzymes produced the same patterns
of DNA cleavage and responded to CPT [albeit the Hs-
Top1mt less than Hs-Top1 (28)] (prominent cleavage sites
labeled 18, 44, 66 and 93 in Figure 7A), the archaeal en-
zyme only produced three weak cleavage sites (labeled 72,
80 and 93). The first two were independent of CPT and did
not match the sites induced by the vertebrate enzymes (Fig-
ure 7A). Cs-TopIB cleavage was also not stimulated by two
non-CPT topoisomerase IB inhibitors, the indenoisoquino-
line LMP744 and lamellarin D (22,54,55) (Figure 7B). Test-
ing the Cs-TopIB-Y477F catalytic mutant (see Supplemen-
taryFigure S3C) confirmed that the unique cleavage sites in-
duced by Cs-TopIB were specific (Figure 7B). The DNA se-
quence of the three cleavage sites detected in the pSK-DNA
were different, thereby showing no specific consensus cleav-
age sequence, and the one that had weak sensitivity to CPTs
(site 93) (Figure 7B) showed a guanine +1, which is usually
the case for the eukaryotic TopIB enzymes (56).
DISCUSSION
Up to now, more than 50 genes encoding Type IB enzymes
have been identified in cultured and uncultured Thaumar-
chaeota. Our phylogenetic analysis show that all type IB en-
zymes from Thaumarchaeota form a monophyletic group
that branch as sister group of the eukaryotic DNA topoi-
somerases IB. We found that the gene encoding the type IB
DNA topoisomerase of the thaumarchaeon N. viennensis is
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Figure 4. Cs-TopIB supercoiled DNA relaxation assays over broad tem-
perature range. (A) Effect of the temperature: assays were carried out for 2
min using 200 ng of pBR322 as a substrate of negative supercoiled DNA
and 50 nM of Cs-TopIB protein at the indicated temperatures (◦C). (B)
Time courses assays were performed using 200 ng of pBR322 as a sub-
strate of negative supercoiled DNA and 50 nM of Cs-TopIB protein at the
indicated times (s). In both panel, Sc−: negatively supercoiled DNA; R:
relaxed DNA; C: control reaction without enzyme.
Figure 5. Cs-TopIB thermoresistance, relaxation of both positively and
negatively supercoiled DNA and activity in the absence of magnesium.
(A) Cs-TopIB was pre-heated at the indicated temperatures for 20 min,
then assayed for pBR322 relaxation for 20 min at 65◦C using 200 ng of
pBR322 and 130 nM of Cs-TopIB protein. (B) Assays on negatively and
positively supercoiled DNA: negatively (SC−) and positively (SC+) super-
coiled pBR322were assayed for relaxationwithEscherichia coliTopIA and
Cs-TopIB enzymes at 30◦C for 30 min in their respective reaction buffers
(see panel C and Supplementary Figure S4 for time-course experiments).
(C) Assays were carried out for 30 min at 30◦C with 0.8 nM of Hs-Top1, 2
nMofCs-TopIB and 6.8 nMofHs-Top1mt and 200 ng of pBR322 as a neg-
atively supercoiled substrate. Mg2+ was added at the indicated final con-
centrations. ‘C’: reaction without enzyme. In all panels, SC−: negatively
supercoiled DNA; SC+: positively supercoiled DNA; R: relaxed DNA.
Figure 6. CPT resistance of Cs-TopIB on DNA relaxation. (A) Time
courses assays were carried out from 1 to 30 min at 30◦C in the presence
of 5% DMSO or 50 mM of CPT and 200 ng of a negatively supercoiled
pBR322. (B) Time courses assays were carried out from 1 to 30 min at
30◦C in the presence of 5% DMSO or 50 mM of CPT and 200 ng of a
positively supercoiled pBR322. Assays in (A) or (B) were done with addi-
tion of 10, 6 and 5 nM of Cs-TopIB, Hs-Top1mt and Hs-Top1 respectively.
SC−: negatively supercoiled DNA; SC+: positively supercoiled DNA; R:
relaxed DNA; C:control reaction without enzyme. Asterisk represents the
open circular form in the control and a mix of the open form and the en-
tirely relaxed form of the plasmids for the assays with enzymes.
expressed and that the enzyme isolated from Ca. C. subter-
raneum exhibits canonical characteristics of type IB topoi-
somerases, apart from its temperature stability, sequence
selectivity and resistance to CPTs and non-CPT Top1 in-
hibitors. The confirmation of the topoisomerase IB typical
biochemical activity pattern for the purified thaumarchaeal
TopIB enzyme and the detection of transcriptional activity
of the corresponding gene in an available laboratory strain
strongly suggest that type IB DNA topoisomerases are ac-
tive in Thaumarchaeota and confirm that topIB genes could
be considered as hallmark genes for Thaumarchaeota.
The phylogenetic tree of Figure 1 suggests that a type IB
enzyme was present in the common ancestor of Archaea
and Eukarya and was later on lost in Euryarchaea and Cre-
narchaeota, as previously proposed (32). However, several
authors have suggested these last years that Eukarya and
Archaea do not share a last common ancestor but that Eu-
karya are sister group of an archaeal ‘TACK’ superphy-
lum grouping Thaumarchaeota, Aigarchaeota (Ca. C. sub-
terraneum), Crenarchaeota and Korarchaeota (57). If this
were the case, the long form of type IB enzyme should have
been introduced in Archaea during the diversification of
this domain. Recently, it has been proposed that Eukarya
are a sister group of a newly proposed archaeal phylum,
Lokiarchaeota, another putative member of the ‘TACK’
superphylum (39). We failed to detect a type IB topoiso-
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Figure 7. Sequence selectivity and cleavage complexes induced by Cs-TopIB, Hs-Top1mt and Hs-Top1 in the absence and presence of Top1 inhibitors. (A)
3′-end 32P-end labeled pSK-DNAwas incubated with Cs-TopIB, Hs-Top1 or Hs-Top1mt at 25◦C for 20 min in the presence of the indicated concentrations
of CPTs (CPT in M). Cleavage sites are indicated to the left with corresponding sequences to the right (cleavage indicated by caret). (B) Additional
experiments with the catalytic dead (see Supplementary Figures S2–S3) Cs-TopIB-Y477F enzyme compared to the wild-type enzyme and with additional
Top1 inhibitors: the indenoisoquinoline LMP744 and the marine alkaloid lamellarin D (LamD).
merase in published sequences of Lokiarchaea. However,
since genomes of Lokiarchaea are presently incomplete, it
is not yet possible to draw a definitive conclusion on this
matter. In fact, the exact topology of the tree of life and the
evolutionary relationships between Archaea and Eukarya
is still a controversial issue (58). In any scenario, the ori-
gin of type IB enzymes remains mysterious. The short form
is present in only around half of bacterial phyla and, in
these phyla, is present in between 2 and 25% of sequenced
genomes (our unpublished observation), raising doubt on
the presence of these enzymes in the ancestor of bacteria.
Type IB enzymes might have been transferred in modern
organisms from now extinct cellular or viral lineages, the
viral scenario being supported by homology between type
IB enzymes and viral tyrosine recombinases (59).
The enzyme isolated from the putative thermophilic un-
cultivated strain Ca. C. subterraneum exhibits the canon-
ical activities of type IB enzymes, relaxing both positive
and negative supercoiledDNAwithout divalent metal (Fig-
ure 5). This result is not surprising considering its high se-
quence and structural similarities with the eukaryotic en-
zymes (Figure 3). We found that the gene encoding the type
IB DNA topoisomerase of the thaumarchaeon N. viennen-
sis is expressed whenN. viennensis is growing in exponential
phase, suggesting a role for the protein in rapidly growing
cells (Figure 2). As in Eukaryotes, the thaumarcheal TopIB
is a plausible candidate to eliminate positive supercoils pro-
duced ahead of DNA replication forks, as well as the posi-
tive and negative supercoiled DNA produced in the course
of transcription (6,10,60,61). However, these tasks could
also be realized by the canonical archaeal DNA topoiso-
merase VI (type IIB), which is also present in the genomes
of all Thaumarchaea analyzed so far. Interestingly, some
Thaumarchaea lack a gene encoding a type IA enzyme (32).
This is striking because all other organisms from the three
domains of life without exception encode either one or sev-
eral type IA enzymes (4). This indicates that the type IB en-
zyme should be able to replace some critical function of type
IA enzymes in these Thaumarchaeota. Further characteri-
zation of the role of the type IB enzyme in the physiology of
the Thaumarchaeota will require developing genetic tools
for these fascinating microorganisms.
Type IB DNA topoisomerases are very important targets
for antitumoral drugs in human (22). In particular, drugs
of the CPT family, like topotecan and irinotecan, are com-
monly used in chemotherapy. We report here that CPT only
interacts weakly with the thaumarchaeal TopIB by stabi-
lizing one of the cleavage complexes and inducing DNA
cleavage at the preferred guanosine +1 sequence (56) (Fig-
ure 7). However, in contrast to the situation observed with
the human type IB enzymes, CPT had no effect on the re-
laxation activities of the archaeal enzyme, despite the con-
servation in the Cs-TopIB of the catalytic tetrad (in hu-
man : R488, K532, R590 and H632), and of the amino
acids implicated with the CPT resistance (in human : F361,
R364, D533, N722) (62). This is likely explained by the fact
that CPTs and the other non-CPT Top1 inhibitors tested
(the indenoisoquinoline LMP744 and the natural product
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lamellarin D) act as interfacial inhibitors and require spe-
cific DNA sequences for trapping the Top1 cleavage com-
plexes (22). Drug resistance can also be related to protein
sequence differences (see Figure 3 and Supplementary Fig-
ure S2) as the drugs require specific interactions with amino
acid residue for trapping topoisomerase IB enzymes (22,63).
The difference in DNA sequence selectivity between the Cs-
TopIB and Hs-Top1 are likely to explain the resistance of
Cs-TopIB to CPTs and other anticancer Top1 inhibitors.
Finally, the thermoresistance of Cs-TopIB makes the en-
zyme stable and easy to purify in E. coli (Supplementary
Figure S3A). Cs-TopIB can work over a wide range of tem-
peratures (Figure 4A), whereas the vertebrate Top1 are in-
activated at 65◦C (50), a property that could be useful for
biochemical characterization and biotechnological applica-
tions. Importantly, the archaeal type IB topoisomerases are
much more similar to the eukaryotic enzymes than the Vac-
cinia virus type IB topoisomerase, which has been widely
used asmodel system to understand human enzyme (Figure
1). These characteristics suggest that the Cs-TopIB or oth-
ers thaumarchaeal TopIB might be promising new models
for evolutionary, mechanistic and structural studies of the
type IB DNA topoisomerases.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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